Tim Draper: Fiat currencies may gradually transition to Bitcoin, and governments should hold enough Bitcoin
Foresight News reports that renowned Silicon Valley investor and Bitcoin advocate Tim Draper stated at the "Bitcoin 2026" conference that the evolution of money may progress from fiat currencies to stablecoins, ultimately converging on Bitcoin. According to him, it is irresponsible for enterprises with significant cash reserves not to allocate funds to Bitcoin. He recommends that companies allocate at least 5% to 15% of their assets to Bitcoin, families should hold at least six months' worth of living expenses in Bitcoin, and governments should retain sufficient Bitcoin reserves to address monetary crises. Citing the collapse of Silicon Valley Bank as an example, he pointed out that once a systemic banking crisis occurs, enterprises need assets independent of the banking system to ensure salary payments and maintain operations.
He also noted that he once lost Bitcoin in the Mt.Gox incident but was later motivated to re-enter the market after seeing Bitcoin used for cross-border remittances among unbanked populations in Africa and Southeast Asia. The adoption of Bitcoin has far exceeded expectations, with banks and governments now rolling out the red carpet for this asset. Humanity, he said, stands on the threshold of an anthropological transformation comparable to the invention of money itself.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Most panda coin types from the 2026 edition steadily rebounded in August
Competition in US oral weight-loss drugs intensifies! Eli Lilly (LLY.US) Foundayo captures 30% of new patients, narrowing Novo Nordisk's (NVO.US) first-mover advantage
Eli Lilly stated on Monday that its oral weight-loss drug, Foundayo, has captured over 30% of the market share among new patients in the US oral obesity treatment market, narrowing the early lead achieved by Danish competitor Novo Nordisk with its Wegovy oral tablets.

2-Yr Benchmark Govt Yields - Germany vs Other Nations
2-Yr Benchmark Govt Yields - U.S. vs Other Nations
